Article Per Year (5 Year)
p-Index From 2020 - 2025
0.444
P-Index
This Author published in this journals
All Journal MEDICINUS Media Dermato-Venereologica Indonesiana
Siti Efrida Fiqnasyani
Unknown Affiliation
Biochemistry, Genetics & Molecular Biology Health Professions Immunology & microbiology Medicine & Pharmacology Neuroscience Public Health

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
TERAPI PSORIASIS DI MASA PANDEMI COVID-19 Siti Efrida Fiqnasyani; Arie Kusumawardani
Media Dermato-Venereologica Indonesiana Vol 50 No 2 (2023): Media Dermato Venereologica Indonesiana
Publisher : Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33820/mdvi.v50i2.315

Abstract

Psoriasis is a chronic residive inflammatory skin disease caused by an autoimmune process. The worldwide prevalence of psoriasis ranges from 2-3% with the prevalence in Asia tends to be low, which is less than 0.5%. Psoriasis consists of erythematous scaly plaques and occurs most commonly on the elbows, knees, scalp, and lower back. Because of the reported frequent recurrences, psoriasis requires maintenance therapy in the form of systemic therapy such as retinoids, methotrexate, alefacept, and efalizumab. Coronavirus disease 2019 (COVID-19) is a respiratory infection caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and is highly contagious. The COVID-19 pandemic has a negative impact on psoriasis management and healthcare delivery. Infection of COVID-19 and its related medications can also affect the clinical severity and exacerbation in patient with psoriasis. Inadequate management of COVID-19 can trigger a cytokine storm and cause acute respiratory distress syndrome (ARDS), sepsis, and other complications. COVID-19 patients who experience a cytokine storm with elevated IL-6 and IL-17 may potentially experience psoriasis exacerbations. Biological therapy for psoriasis during pandemic should be carefully considered according to the individual patient’s condition.
Profile of Candidiasis Patients in RSUD Dr. Moewardi Surakarta January 2016−December 2019 Nurrachmat Mulianto; Siti Efrida Fiqnasyani
MEDICINUS Vol. 35 No. 2 (2022): MEDICINUS
Publisher : PT Dexa Medica

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (199.977 KB) | DOI: 10.56951/medicinus.v35i2.97

Abstract

Background: Candidiasis is caused by Candida sp. infection, mainly Candida albicans. The skin, mucous membranes, nails, and digestive tract are organs that can be affected by this infection. The risk of infection is higher in immunocompromised individuals. Objective: To determine the profile of candidiasis patients in Dr. Moewardi Hospital Surakarta between January 2016-December 2019. Method: This is a retrospective, descriptive study that evaluate the distribution of sex, age, primary diagnosis, comorbidities, and candidiasis type among candidiasis patients in RSUD Dr. Moewardi. Results: During study period, there were 177 candidiasis patients (147 outpatients and 30 inpatients). Pseudohyphae was seen in all inpatients’ KOH test. Majority of the patients are women (77,97%), age distribution varies between outpatients and inpatients. Cutaneous candidiasis was found in 53,74% outpatients and 66,67% inpatients. Type 2 diabetes mellitus was the most frequent (20%) comorbidity among those patients. Topical miconazole 2% and systemic fluconazole 150 mg were given to 42,37% and 33,90% patients, respectively.
Co-Authors Arie Kusumawardani Nurrachmat Mulianto